Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionFisher Asset Management, LLC
Latest Disclosed Ownership31,158 shares
Latest Disclosed Value $ 13,913,603
Fisher Asset Management, LLC reports 23.55% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 5, 2026 - Fisher Asset Management, LLC filed a 13F-HR form disclosing ownership of 31,158 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $13,913,293 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 25,218 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 23.55% during the quarter. The current value of the position is $13,922,329 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 31,158 5,940 23.55 13,914 21.70 0.0047
2026-02-09 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 25,218 -741 -2.85 11,433 12.45 0.0039
2025-11-12 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,959 204 0.79 10,167 -11.34 0.0037
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,755 -4,914 -16.02 11,466 -22.89 0.0046
2025-05-14 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,669 761 2.54 14,869 23.46 0.0064
2025-02-05 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 29,908 2,886 10.68 12,044 -4.16 0.0048
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 27,022 -1,083 -3.85 12,568 -4.60 0.0052
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 28,105 582 2.11 13,173 14.51 0.0057
2024-05-09 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 27,523 843 3.16 11,505 5.97 0.0054
2024-03-05 2023-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 26,680 334 1.27 10,856 18.50 0.0057
2024-02-06 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,454 108 10,764 0.0053
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,346 -3,105 -10.54 9,162 -11.61 0.0052
2023-12-12 2023-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 29,451 2,018 7.36 10,364 19.91 0.0057
2023-08-08 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 29,464 2,031 10 0.0057
2023-12-12 2023-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 27,433 1,364 5.23 8,644 123,371.43 0.0052
2023-05-01 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,493 424 8 0.0051
2023-02-03 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,069 486 1.90 8 -99.91 0.0051
2022-11-08 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,583 -670 -2.55 7,407 0.12 0.0056
2022-08-09 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,253 1,669 6.79 7,398 15.31 0.0052
2022-05-05 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,584 -687 -2.72 6,416 15.60 0.0038
2022-02-02 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 25,271 1,157 4.80 5,550 26.89 0.0031
2021-10-26 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,114 -899 -3.59 4,374 -13.27 0.0027
2021-07-27 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,013 -1,040 -3.99 5,043 -9.93 0.0032
2021-04-27 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,053 1,226 4.94 5,599 -4.58 0.0039
2021-01-29 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,827 353 1.44 5,868 -11.89 0.0044
2020-11-12 2020-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 24,474 1,151 4.94 6,660 -1.64 0.0058
2020-11-10 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,474 1,151 6,660 5,655.4887
2020-08-07 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,323 -428 -1.80 6,771 19.80 0.0066
2020-04-28 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,751 1,398 6.25 5,652 15.49 0.0070
2020-02-12 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 22,353 228 1.03 4,894 30.58 0.0049
2019-10-29 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 22,125 276 1.26 3,748 -6.46 0.0041
2019-07-30 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 21,849 6,660 43.85 4,007 43.41 0.0044
2019-04-22 2019-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 15,189 12,768 527.39 2,794 596.76 0.0033
2019-04-22 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,421 0 401
2019-01-25 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,421 223 10.15 401 -5.42 0.0005
2018-10-23 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,198 2,198 424 0.0005
2018-07-09 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -7,395 -100.00 0 -100.00
2018-04-20 2018-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 7,395 2,306 45.31 1,205 57.93 0.0015
2018-04-19 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,395 2,306 1,205
2018-01-24 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,089 105 2.11 763 0.66 0.0010
2017-10-17 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,984 -962 -16.18 758 -1.04 0.0011
2017-07-12 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,946 733 14.06 766 34.39 0.0012
2017-04-24 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,213 45 0.87 570 49.61 0.0009
2017-01-10 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,168 0 0.00 381 -15.52 0.0007
2016-10-11 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,168 56 1.10 451 -2.17 0.0008
2016-07-12 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,112 -43 -0.83 461 9.50 0.0009
2016-04-18 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,155 -388 -7.00 421 -39.60 0.0008
2016-01-14 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,543 615 12.48 697 35.87 0.0013
2015-10-20 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,928 550 12.56 513 -5.18 0.0011
2015-07-17 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,378 -8 -0.18 541 4.64 0.0011
2015-04-30 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,386 4,386 0.00 517 0.0010
2015-01-29 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -4,593 -100.00 0 -100.00
2014-10-20 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,593 -2,160 -31.99 516 -19.25 0.0011
2014-07-25 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,753 6,753 639 0.0013
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.